Investigational pharmacologic treatment for liver disease

Abstract

Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.

• hepatitis B virus
• hepatitis C virus
• non-alcoholic steatohepatitis
• nucleoside analogues
• nucleotide analogues
• pegylated interferon
• primary sclerosing cholangitis
• ursodeoxycholic acid
• ursodiol